All About Multiple Sclerosis

More MS news articles for December 2003

Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis?

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14653852&dopt=Abstract

Acta Neurol Scand. 2004 Jan;109(1):61-5
Casoni F, Merelli E, Bedin R, Sola P, Bertolotto A, Faglioni P.
Department of Neurology, University of Modena, Modena, Italy Laboratory of Clinical Neurobiology, University of Turin, Orbassano, Italy.

BACKGROUND :

Interferon beta (INFbeta) may induce the expression of several proteins, including neopterin, considered a biological marker of INFbeta activity.

OBJECTIVES :

The aim of this study was to determine the serum neopterin concentration at the beginning of, and during, IFNbeta-1a therapy in relapsing-remitting multiple sclerosis (r-r MS) patients, and to look for a possible correlation between protein synthesis and the clinical course of the disease.

METHODS :

Thirteen r-r MS patients were treated with INFbeta-1a (i.m. 6 MIU/week) for 2 years.

Blood samples for neopterin determinations were taken daily over a period of 1 week at the end of each 6 months of therapy, and tested for neutralizing antibodies (NABs).

RESULTS :

Neopterin levels peaked 24-48 h post-injection and returned to baseline after 120 h.

After 1 year of therapy, four patients dropped out of the study because of progression of the disease: in these subjects a significant decrement of neopterin was observed.

CONCLUSION :

Neopterin baseline values were not found to decrease over the 2 years of therapy, and neopterin may be considered to be a useful marker of responsiveness to IFNbeta.